Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group

Maria Grazia Daidone; John A. Foekens; Nadia Harbeck; John Martens; Nils Brunner; Christoph Thomssen; Jacqueline A. Hall; Roberto Salgado; Juergen Dittmer; Anneke Geurts-Moespot; M. Joe Duffy; Fred C.G.J. Sweep; Manfred Schmitt; H. Allgayer; F. Barlesi; N. Bekka; P. M.J.E. Berns; F. Cardoso; I. J. Christensen; J. Ciccolini; J. C. Diaz-Chico; S. Eppenberger-Castori; M. Ferno; D. Figarella-Branger; M. Gion; O. Gluz; M. Hegi; J. Kos; M. Ladomery; T. T. Lah; K. Lambein; P. J. Lamy; L. Libbrecht; C. Liedtke; B. Linderholm; T. Lively; S. Loibl; A. E. Lykkesfeldt; P. M. Martin; C. Mazouni; V. Muller; X. Muracciole; L. Ouafik; K. Pantel; A. Paradiso; S. Pastorekova; A. Rhodes; P. H.J. Riegman; D. Rimoldi; S. Romain; I. Skvortsova; S. Sleijfer; P. N. Span; F. Spyratos; M. Talieri; S. Taube; S. Tejpar; G. Thomas; E. Ulukaya

doi:10.1016/S1359-6349(12)70021-6

Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group

Maria Grazia Daidone, John A. Foekens, Nadia Harbeck, John Martens, Nils Brunner, Christoph Thomssen, Jacqueline A. Hall, Roberto Salgado, Juergen Dittmer, Anneke Geurts-Moespot, M. Joe Duffy, Fred C.G.J. Sweep, Manfred Schmitt, H. Allgayer, F. Barlesi, N. Bekka, P. M.J.E. Berns, F. Cardoso, I. J. Christensen, J. CiccoliniJ. C. Diaz-Chico, S. Eppenberger-Castori, M. Ferno, D. Figarella-Branger, M. Gion, O. Gluz, M. Hegi, J. Kos, M. Ladomery, T. T. Lah, K. Lambein, P. J. Lamy, L. Libbrecht, C. Liedtke, B. Linderholm, T. Lively, S. Loibl, A. E. Lykkesfeldt, P. M. Martin, C. Mazouni, V. Muller, X. Muracciole, L. Ouafik, K. Pantel, A. Paradiso, S. Pastorekova, A. Rhodes, P. H.J. Riegman, D. Rimoldi, S. Romain, I. Skvortsova, S. Sleijfer, P. N. Span, F. Spyratos, M. Talieri, S. Taube, S. Tejpar, G. Thomas, E. Ulukaya

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

5 Citations (Scopus)

Résumé

The increasing demand for personalized cancer therapy requires a strong, intense, and continuous collaboration between pre-clinical and clinical investigators. As a part of the EORTC Translational Research Divison, the EORTC PathoBiology Group (EORTC PBG), focuses on discovery and validation of cancer biomarkers, providing both scientific evidence as well as quality assurance. The clinically relevant target-identification and validation studies carried out in the last decades within the EORTC PBG represent a paradigm for EORTC studies in which laboratory investigations on human biologic material are used to support the development of drugs directed to defined target molecules. The experience acquired within the EORTC PBG with respect to standardization of cancer biomarker test kits and reagents, quality assessment/assurance of cancer biomarker determinations, development of standard operating procedures for assessment of these markers as well as instruction of methodologies and teaching of ethical issues represent a valuable contribution of the EORTC PBG to the onco-translational strategies of the EORTC.

langue originale	Anglais
Pages (de - à)	120-127
Nombre de pages	8
journal	European Journal of Cancer, Supplement
Volume	10
Numéro de publication	1
Les DOIs	https://doi.org/10.1016/S1359-6349(12)70021-6
état	Publié - 1 mars 2012

Accès au document

10.1016/S1359-6349(12)70021-6

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Daidone, M. G., Foekens, J. A., Harbeck, N., Martens, J., Brunner, N., Thomssen, C., Hall, J. A., Salgado, R., Dittmer, J., Geurts-Moespot, A., Duffy, M. J., Sweep, F. C. G. J., Schmitt, M., Allgayer, H., Barlesi, F., Bekka, N., Berns, P. M. J. E., Cardoso, F., Christensen, I. J., ... Ulukaya, E. (2012). Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. European Journal of Cancer, Supplement, 10(1), 120-127. https://doi.org/10.1016/S1359-6349(12)70021-6

@article{75bb2230d2fc4d6ca7a2964bf6ad23cf,

title = "Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group",

abstract = "The increasing demand for personalized cancer therapy requires a strong, intense, and continuous collaboration between pre-clinical and clinical investigators. As a part of the EORTC Translational Research Divison, the EORTC PathoBiology Group (EORTC PBG), focuses on discovery and validation of cancer biomarkers, providing both scientific evidence as well as quality assurance. The clinically relevant target-identification and validation studies carried out in the last decades within the EORTC PBG represent a paradigm for EORTC studies in which laboratory investigations on human biologic material are used to support the development of drugs directed to defined target molecules. The experience acquired within the EORTC PBG with respect to standardization of cancer biomarker test kits and reagents, quality assessment/assurance of cancer biomarker determinations, development of standard operating procedures for assessment of these markers as well as instruction of methodologies and teaching of ethical issues represent a valuable contribution of the EORTC PBG to the onco-translational strategies of the EORTC.",

keywords = "Biobanking, Biomarkers, Discovery, Personalized cancer therapy, Quality assessment, Quality assurance, Standard Operating Procedures, Translational strategies, Validation",

author = "Daidone, {Maria Grazia} and Foekens, {John A.} and Nadia Harbeck and John Martens and Nils Brunner and Christoph Thomssen and Hall, {Jacqueline A.} and Roberto Salgado and Juergen Dittmer and Anneke Geurts-Moespot and Duffy, {M. Joe} and Sweep, {Fred C.G.J.} and Manfred Schmitt and H. Allgayer and F. Barlesi and N. Bekka and Berns, {P. M.J.E.} and F. Cardoso and Christensen, {I. J.} and J. Ciccolini and Diaz-Chico, {J. C.} and S. Eppenberger-Castori and M. Ferno and D. Figarella-Branger and M. Gion and O. Gluz and M. Hegi and J. Kos and M. Ladomery and Lah, {T. T.} and K. Lambein and Lamy, {P. J.} and L. Libbrecht and C. Liedtke and B. Linderholm and T. Lively and S. Loibl and Lykkesfeldt, {A. E.} and Martin, {P. M.} and C. Mazouni and V. Muller and X. Muracciole and L. Ouafik and K. Pantel and A. Paradiso and S. Pastorekova and A. Rhodes and Riegman, {P. H.J.} and D. Rimoldi and S. Romain and I. Skvortsova and S. Sleijfer and Span, {P. N.} and F. Spyratos and M. Talieri and S. Taube and S. Tejpar and G. Thomas and E. Ulukaya",

year = "2012",

month = mar,

day = "1",

doi = "10.1016/S1359-6349(12)70021-6",

language = "English",

volume = "10",

pages = "120--127",

journal = "European Journal of Cancer, Supplement",

issn = "1359-6349",

number = "1",

}

Daidone, MG, Foekens, JA, Harbeck, N, Martens, J, Brunner, N, Thomssen, C, Hall, JA, Salgado, R, Dittmer, J, Geurts-Moespot, A, Duffy, MJ, Sweep, FCGJ, Schmitt, M, Allgayer, H, Barlesi, F, Bekka, N, Berns, PMJE, Cardoso, F, Christensen, IJ, Ciccolini, J, Diaz-Chico, JC, Eppenberger-Castori, S, Ferno, M, Figarella-Branger, D, Gion, M, Gluz, O, Hegi, M, Kos, J, Ladomery, M, Lah, TT, Lambein, K, Lamy, PJ, Libbrecht, L, Liedtke, C, Linderholm, B, Lively, T, Loibl, S, Lykkesfeldt, AE, Martin, PM, Mazouni, C, Muller, V, Muracciole, X, Ouafik, L, Pantel, K, Paradiso, A, Pastorekova, S, Rhodes, A, Riegman, PHJ, Rimoldi, D, Romain, S, Skvortsova, I, Sleijfer, S, Span, PN, Spyratos, F, Talieri, M, Taube, S, Tejpar, S, Thomas, G & Ulukaya, E 2012, 'Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group', European Journal of Cancer, Supplement, VOL. 10, Numéro 1, p. 120-127. https://doi.org/10.1016/S1359-6349(12)70021-6

Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. / Daidone, Maria Grazia; Foekens, John A.; Harbeck, Nadia et al.
Dans: European Journal of Cancer, Supplement, Vol 10, Numéro 1, 01.03.2012, p. 120-127.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - Identification, validation and clinical implementation of cancer biomarkers

T2 - Translational strategies of the EORTC PathoBiology Group

AU - Daidone, Maria Grazia

AU - Foekens, John A.

AU - Harbeck, Nadia

AU - Martens, John

AU - Brunner, Nils

AU - Thomssen, Christoph

AU - Hall, Jacqueline A.

AU - Salgado, Roberto

AU - Dittmer, Juergen

AU - Geurts-Moespot, Anneke

AU - Duffy, M. Joe

AU - Sweep, Fred C.G.J.

AU - Schmitt, Manfred

AU - Allgayer, H.

AU - Barlesi, F.

AU - Bekka, N.

AU - Berns, P. M.J.E.

AU - Cardoso, F.

AU - Christensen, I. J.

AU - Ciccolini, J.

AU - Diaz-Chico, J. C.

AU - Eppenberger-Castori, S.

AU - Ferno, M.

AU - Figarella-Branger, D.

AU - Gion, M.

AU - Gluz, O.

AU - Hegi, M.

AU - Kos, J.

AU - Ladomery, M.

AU - Lah, T. T.

AU - Lambein, K.

AU - Lamy, P. J.

AU - Libbrecht, L.

AU - Liedtke, C.

AU - Linderholm, B.

AU - Lively, T.

AU - Loibl, S.

AU - Lykkesfeldt, A. E.

AU - Martin, P. M.

AU - Mazouni, C.

AU - Muller, V.

AU - Muracciole, X.

AU - Ouafik, L.

AU - Pantel, K.

AU - Paradiso, A.

AU - Pastorekova, S.

AU - Rhodes, A.

AU - Riegman, P. H.J.

AU - Rimoldi, D.

AU - Romain, S.

AU - Skvortsova, I.

AU - Sleijfer, S.

AU - Span, P. N.

AU - Spyratos, F.

AU - Talieri, M.

AU - Taube, S.

AU - Tejpar, S.

AU - Thomas, G.

AU - Ulukaya, E.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - The increasing demand for personalized cancer therapy requires a strong, intense, and continuous collaboration between pre-clinical and clinical investigators. As a part of the EORTC Translational Research Divison, the EORTC PathoBiology Group (EORTC PBG), focuses on discovery and validation of cancer biomarkers, providing both scientific evidence as well as quality assurance. The clinically relevant target-identification and validation studies carried out in the last decades within the EORTC PBG represent a paradigm for EORTC studies in which laboratory investigations on human biologic material are used to support the development of drugs directed to defined target molecules. The experience acquired within the EORTC PBG with respect to standardization of cancer biomarker test kits and reagents, quality assessment/assurance of cancer biomarker determinations, development of standard operating procedures for assessment of these markers as well as instruction of methodologies and teaching of ethical issues represent a valuable contribution of the EORTC PBG to the onco-translational strategies of the EORTC.

AB - The increasing demand for personalized cancer therapy requires a strong, intense, and continuous collaboration between pre-clinical and clinical investigators. As a part of the EORTC Translational Research Divison, the EORTC PathoBiology Group (EORTC PBG), focuses on discovery and validation of cancer biomarkers, providing both scientific evidence as well as quality assurance. The clinically relevant target-identification and validation studies carried out in the last decades within the EORTC PBG represent a paradigm for EORTC studies in which laboratory investigations on human biologic material are used to support the development of drugs directed to defined target molecules. The experience acquired within the EORTC PBG with respect to standardization of cancer biomarker test kits and reagents, quality assessment/assurance of cancer biomarker determinations, development of standard operating procedures for assessment of these markers as well as instruction of methodologies and teaching of ethical issues represent a valuable contribution of the EORTC PBG to the onco-translational strategies of the EORTC.

KW - Biobanking

KW - Biomarkers

KW - Discovery

KW - Personalized cancer therapy

KW - Quality assessment

KW - Quality assurance

KW - Standard Operating Procedures

KW - Translational strategies

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=84863420901&partnerID=8YFLogxK

U2 - 10.1016/S1359-6349(12)70021-6

DO - 10.1016/S1359-6349(12)70021-6

M3 - Article

AN - SCOPUS:84863420901

SN - 1359-6349

VL - 10

SP - 120

EP - 127

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

IS - 1

ER -